JW Therapeutics

  • JW Therapeutics closes USD100m Series B financing round

    JW Therapeutics announced the completion of a US$100 million Series B round of financing, the investment was co-led by CPE and Mirae Asset, jointed by CR-CP Life Science Fund and Oriza Holdings, as well as existing investors including Loyal Valley Capital, Temasek, Sequoia Capital China, ARCH Venture Partners, Juno Therapeutics, a Bristol Myers Squibb company, and WuXi AppTec.